Literature DB >> 2937355

Nitrendipine attenuates the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia in rats.

J R Michael, T P Kennedy, P Buescher, I Farrukh, R Lodato, P C Rock, J Gottlieb, G Gurtner, S M de la Monte, G M Hutchins.   

Abstract

We designed experiments to determine whether intermittent hypoxia would produce significant pathologic and physiologic changes in rats and whether pretreatment with a calcium channel blocker, nitrendipine, would reduce the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia. Intermittent exposure to hypobaric hypoxia (0.5 atmospheres) 10 h a day for 30 days increased the hematocrit (65 +/- 1 versus 42 +/- 1%, mean +/- SEM), right ventricular systolic pressure (33 +/- 1 versus 20 +/- 1 mmHg), and right ventricular weight adjusted for body weight (RV/BW) (126 +/- 6 versus 60 +/- 2 mg/100 g) in male Sprague-Dawley rats. Intermittent hypoxia also increased the percentage of small pulmonary vessels with muscle (76 +/- 3 versus 19 +/- 5%) and the thickness of the vessel wall as a percentage of the total vessel diameter (34 +/- 1 versus 22 +/- 1%). Nitrendipine (10 mg/kg) prevented the acute increase in right ventricular systolic pressure caused by hypoxia. Chronic treatment with nitrendipine (10 mg/kg given twice a day by gavage for 30 days) significantly reduced the increase in hematocrit (61 +/- 1 versus 65 +/- 1%), right ventricular systolic pressure (29 +/- 1 versus 33 +/- 1 mmHg), and RV/BW (108 +/- 4 versus 126 +/- 6 mg/100 g) caused by hypoxia. Chronic treatment with nitrendipine also reduced the percentage of small pulmonary vessels with muscle (38 +/- 8 versus 76 +/- 3%) and prevented the increase in vessel wall thickness (20 +/- 2 versus 34 +/- 1%). Thus, nitrendipine treatment significantly reduces the right ventricular hypertrophy and pulmonary vascular changes caused by intermittent hypoxia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2937355     DOI: 10.1164/arrd.1986.133.3.375

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  7 in total

1.  Prolonged hypoxia increases pulmonary vascular smooth muscle cytosolic calcium.

Authors:  R L Vender; E M Saab
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-08       Impact factor: 2.416

2.  Role of endothelial cells in the proliferative response of cultured pulmonary vascular smooth muscle cells to reduced oxygen tension.

Authors:  R L Vender
Journal:  In Vitro Cell Dev Biol       Date:  1992-06

Review 3.  New approaches to the treatment of pulmonary hypertension: from bench to bedside.

Authors:  Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Mar-Apr       Impact factor: 2.644

Review 4.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

5.  Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia.

Authors:  J S Thompson; W Sheedy; A H Morice
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 6.  The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.

Authors:  Steven C Pugliese; Jens M Poth; Mehdi A Fini; Andrea Olschewski; Karim C El Kasmi; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-21       Impact factor: 5.464

7.  Cardiopulmonary effects in awake rats four and six months after exposure to methyl isocyanate.

Authors:  J S Tepper; M J Wiester; D L Costa; W P Watkinson; M F Weber
Journal:  Environ Health Perspect       Date:  1987-06       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.